Nasdaq:QNCX
Quince Therapeutics, Inc.
A pre-revenue biotech firm investing heavily in R&D while managing significant cash burn and accumulated deficits.
Key Metrics
Investment Thesis
Bull Case
Investors may view QNCX as a high-risk/high-reward opportunity given its large other shareholders equity position of $406.7M which suggests potential for future value realization upon successful clinical milestones. The company's ability to manage long-term assets of $70.4M indicates a solid infrastructure for drug development, positioning it well if any of its pipeline candidates gain regulatory approval.
Bear Case
The stock carries extreme risk due to the massive retained earnings deficit of -$376.5M and zero revenue, meaning the company cannot sustain operations without continuous external capital raises. With cash flow from operations at -$31.9M and total liabilities exceeding shareholders equity, there is a high probability of dilution or bankruptcy if clinical trials fail.
About Quince Therapeutics, Inc.
Quince Therapeutics is a biopharmaceutical company focused on developing novel therapeutic candidates for serious unmet medical needs. The company operates primarily in the United States market with no current commercial revenue, relying on strategic financing to fund its extensive research and development pipeline.
Analysis
Management Discussion
The company reported a net loss of -$56.8M in 2024, widening the operating profit gap compared to the previous year despite lower losses in 2023. While the firm successfully converted investments into cash through investing flows of $21.9M, it continues to burn cash rapidly with operating expenses totaling $57.3M, primarily driven by R&D and administrative costs.
Industry Overview
The biotechnology industry is characterized by high barriers to entry, significant R&D costs, and long development timelines before commercialization. Companies like Quince operate in a sector where success depends on regulatory approvals from the FDA and the ability to navigate complex intellectual property landscapes while managing substantial cash burn rates typical of pre-revenue stages.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $52.0M | $34.6M | $57.3M |
| Operating Income | $-52.0M | $-34.6M | $-57.3M |
| R&D | $25.2M | $9.4M | $18.6M |
| G&A | $26.0M | $17.7M | $17.6M |
| Stock-Based Comp | $16.6M | $5.2M | $4.7M |
| D&A | $204.0K | $322.0K | $186.0K |
| Depreciation | $204.0K | $300.0K | $200.0K |
| Other OpEx | $825.0K | $7.5M | $21.1M |
| Non-Operating Income | $71.0K | $3.0M | $544.0K |
| Interest Income | $1.1M | $3.5M | $2.9M |
| Pre-Tax Income | $-51.9M | $-31.6M | $-56.7M |
| Income Tax | $-284.0K | $197.0K | $87.0K |
| Continuing Ops | $-51.7M | $-31.8M | $-56.8M |
| Discontinued Ops | $0 | $394.0K | $0 |
| Net Income | $-51.7M | $-31.4M | $-56.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-51.7M | $-31.4M | $-56.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $93.7M | $77.4M | $44.0M |
| Prepaid Expenses | $3.6M | $2.4M | $3.3M |
| Other Current Assets | $90.2M | $75.1M | $40.8M |
| Long-Term Assets | $10.2M | $90.5M | $70.4M |
| PP&E (Net) | $393.0K | $234.0K | $315.0K |
| Intangibles | $5.9M | $63.7M | $60.0M |
| Goodwill | $0 | $17.6M | $0 |
| Operating Leases | $291.0K | $385.0K | $498.0K |
| Other LT Assets | $3.6M | $8.5M | $9.5M |
| Total Assets | $103.9M | $167.9M | $114.5M |
| Current Liabilities | $3.1M | $9.6M | $7.3M |
| Accounts Payable | $570.0K | $2.0M | $2.9M |
| Current Leases | $377.0K | $64.0K | $96.0K |
| Other Current Liab | $-377.0K | $4.0M | $-96.0K |
| Long-Term Liabilities | $248.0K | $73.2M | $77.1M |
| LT Operating Leases | $0 | $321.0K | $394.0K |
| Other LT Liab | $248.0K | $72.9M | $76.7M |
| Total Liabilities | $3.3M | $82.8M | $84.3M |
| Shareholders' Equity | $100.6M | $85.1M | $30.1M |
| Retained Earnings | $-288.3M | $-319.6M | $-376.5M |
| AOCI | $-289.0K | $3.0M | $-35.0K |
| Total L&E | $103.9M | $167.9M | $114.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-51.7M | $-31.4M | $-56.8M |
| Non-Cash Adjustments | $23.0M | $19.6M | $20.4M |
| Working Capital Changes | $-15.4M | $-6.5M | $4.6M |
| Cash from Operations | $-44.0M | $-18.3M | $-31.9M |
| Capital Expenditures | $133.0K | $160.0K | $257.0K |
| Cash from Investing | $18.0M | $-5.8M | $21.9M |
| Cash from Financing | $707.0K | $143.0K | $-4.8M |
| FX Effect | $184.0K | $80.0K | $231.0K |
| Net Change in Cash | $-25.1M | $-23.8M | $-14.5M |
| Beginning Cash | $69.7M | $44.6M | $20.8M |
| Ending Cash | $44.6M | $20.8M | $6.2M |
Frequently Asked Questions
How does Quince Therapeutics, Inc. make money?
The company's operations are concentrated entirely in Research & Development activities, specifically driving General and Administrative costs ($17.6M), Research and Development expenses ($18.6M), and Share-based compensation ($4.7M) to advance its drug discovery programs without current commercial product revenue streams.
What are the main risks for QNCX?
Severe liquidity constraints evidenced by a net change in cash of -$14.5M and reliance on external financing given the $-4.8M cash flow from financing; substantial accumulated deficit of -$376.5M indicating long-term burn without profitability; complete lack of revenue generation leading to high volatility dependent on capital markets access.
What is QNCX's competitive advantage?
Access to substantial non-controlling interest equity ($406.7M) providing a strong balance sheet buffer; specialized expertise in identifying novel therapeutic targets for serious diseases; strategic partnerships or licensing opportunities potentially embedded within the significant cash flow from investing activities ($21.9M).
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.